The new LC-MS-based service expands the company’s multiomics portfolio, enabling researchers to integrate metabolite profiling with genomics, transcriptomics and microbiome studies.
Novogene Europe has expanded its multiomics research portfolio with the launch of an Untargeted Metabolomics Service through its Cambridge Omics Centre, adding metabolite-level analysis to its genomics, transcriptomics, sequencing and bioinformatics capabilities.
The service is designed to support discovery-driven research by helping scientists investigate biochemical changes associated with disease mechanisms, microbiome interactions, treatment response and biomarker discovery. According to the company, integrating metabolomics with other omics technologies enables researchers to better connect molecular data with biological function.
The workflow is built around Thermo Scientific Vanquish ultra-high-performance liquid chromatography (UHPLC) coupled with Orbitrap Exploris 120 high-resolution accurate-mass mass spectrometry. Novogene Europe said the platform combines LC-MS analysis with an extensive metabolite reference library to support comprehensive metabolite profiling across suitable biological sample types.
The launch represents the first stage of a broader capability expansion planned for the company’s Cambridge Omics Centre, located within the Bio-Innovation Centre in Cambridge, UK. The company said the investment reflects its strategy to provide integrated multiomics services spanning experimental design, data generation, bioinformatics and biological interpretation for academic, biotechnology and biopharmaceutical researchers.
Tingting Zhou, Vice President of Novogene Europe, said the addition of metabolomics strengthens the company’s ability to provide researchers with a more integrated understanding of biological systems by combining genomic and transcriptomic information with functional biochemical insights.
David Chaplin, General Manager of the Bio-Innovation Centre, said the expanded metabolomics capability would further support researchers and companies operating within the Cambridge life sciences ecosystem.
